Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
Gold
Crude Oil
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries
Athenex Inc
(NQ:
ATNX
)
11.50
USD
+0.08 (+0.70%)
Official Closing Price
Updated: 7:56 PM EST, Jan 21, 2021
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press releases about Athenex Inc
< Previous
1
2
3
4
5
Next >
CEO Dr. Johnson Lau Contracts COVID-19
January 08, 2021
From
GlobeNewswire News Releases
Athenex to Present at the 39th Annual J.P. Morgan Healthcare Conference
January 05, 2021
From
GlobeNewswire News Releases
Almirall announces FDA approval of Klisyri® (tirbanibulin), a new innovative topical treatment for actinic keratosis
December 15, 2020
-- Klisyri® (tirbanibulin) is a novel microtubule inhibitor, indicated for the topical treatment of actinic keratosis (AK) on the face or scalp
From
PR Newswire
Athenex Announces FDA Approval of Klisyri® (Tirbanibulin) for the Treatment of Actinic Keratosis on the Face or Scalp
December 15, 2020
From
GlobeNewswire News Releases
Athenex Presents Updated Phase 3 Data on Survival and Tolerability Associated with Oral Paclitaxel and Encequidar in Patients with Metastatic Breast Cancer
December 09, 2020
From
GlobeNewswire News Releases
Athenex Pharmaceutical Division and Ingenus Pharmaceuticals Announce Availability of Liquid, Ready to Dilute Cyclophosphamide
December 02, 2020
From
GlobeNewswire News Releases
Athenex Announces Data on Oral Paclitaxel and Encequidar to be Presented at the 2020 San Antonio Breast Cancer Symposium (SABCS)
November 17, 2020
From
GlobeNewswire News Releases
Athenex, Inc. Reports Third Quarter Ended September 30, 2020 Financial Results and Provides Corporate Update
November 05, 2020
From
GlobeNewswire News Releases
Athenex, Inc. to Report Third Quarter 2020 Earnings Results on November 5, 2020
October 22, 2020
From
GlobeNewswire News Releases
Axis Therapeutics Announces Research Collaboration with PharmaEssentia for Development of TCR-T Cell Therapy in Taiwan
October 12, 2020
From
GlobeNewswire News Releases
Athenex Oncology launches Your Guide to Facing Metastatic Breast Cancer, a first-of-its-kind self-care resource for people living with metastatic breast cancer (MBC)
October 09, 2020
Guide offers evidence-based recommendations for increasing resilience, reducing stress, maintaining proper nutrition, and other tips to facilitate managing MBC
From
PR Newswire
Athenex Announces FDA Allowance of IND Application for TCRT-ESO-A2, a TCR-T Cell Therapy
September 23, 2020
Athenex’s first T cell therapy product cleared to advance to the first stage of clinical development in the U.S.
From
GlobeNewswire News Releases
Athenex, Inc. Announces Pricing of $110 Million Public Offering of Common Stock
September 10, 2020
From
GlobeNewswire News Releases
Athenex, Inc. Announces Proposed Public Offering of Common Stock
September 08, 2020
From
GlobeNewswire News Releases
Quantum Leap Healthcare Collaborative and Athenex Announce the Selection of Oral Paclitaxel plus Encequidar in Combination with dostarlimab, an anti-PD-1, in the I-SPY 2 TRIAL targeting Stage 2/3 HER2
September 08, 2020
From
GlobeNewswire News Releases
Focusing On Stocks With Great Upside In Past 5 days: $KCAC $TCON $ATNX
September 07, 2020
Tags
The Market Signal
From
The Market Signal
Athenex Announces FDA Acceptance for Filing of U.S. NDA for Oral Paclitaxel and Encequidar in Metastatic Breast Cancer with Priority Review
September 01, 2020
From
GlobeNewswire News Releases
Athenex, Inc. Reports Second Quarter Ended June 30, 2020 Financial Results and Provides Corporate Update
August 06, 2020
From
GlobeNewswire News Releases
Athenex Announces $50 Million Revenue Interest Financing with Sagard Healthcare Royalty Partners
August 06, 2020
From
GlobeNewswire News Releases
Biopharmaceutical Leader Robert J. Spiegel, MD, FACP Appointed to the Athenex Board of Directors
August 04, 2020
Pharmaceutical industry veteran with significant oncology clinical development expertise appointed to Board
From
GlobeNewswire News Releases
Athenex, Inc. to Report Second Quarter 2020 Earnings Results on August 6, 2020
July 27, 2020
From
GlobeNewswire News Releases
CORRECTION-New Research for Immunotherapy Combinations with Paclitaxel Helping in Breast Cancer Fight
July 23, 2020
Tags
Featured News
From
FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
New Research for Immunotherapy Combinations with Paclitaxel Helping in Breast Cancer Fight
July 21, 2020
Tags
Featured News
From
FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
New Research for Immunotherapy Combinations with Paclitaxel Helping in Breast Cancer Fight
July 21, 2020
FN Media Group Presents USA News Group News Commentary
From
PR Newswire
Athenex Appoints Teresa Bair, Esq. as Executive Officer and General Counsel
June 23, 2020
From
GlobeNewswire News Releases
Athenex Announces $225 Million Loan Agreement with Oaktree
June 22, 2020
From
GlobeNewswire News Releases
Athenex Oncology launches Facing MBC Together campaign to address isolation for people living with metastatic breast cancer
June 13, 2020
Campaign features stories of hope, tears, and encouragement from a diverse group of 9 individuals with metastatic breast cancer [MBC]
From
PR Newswire
NASDAQ:ATNX Investor Notice: Investigation over Possible Securities Laws Violations by Athenex, Inc.
June 09, 2020
San Diego, CA -- (SBWIRE) -- 06/09/2020 -- An investigation was announced over potential securities laws violations by Athenex, Inc. in connection with certain financial statements.
From
SBWire - Latest Press Releases
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Athenex, Inc. - ATNX
June 08, 2020
From
GlobeNewswire News Releases
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Athenex, Inc. - ATNX
June 03, 2020
From
GlobeNewswire News Releases
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.